Soluble pig lymphocyte activation gene-3 (LAG-3; CD223) inhibits human-to-pig xenogeneic mixed lymphocyte reaction

被引:0
|
作者
Seon-Soo Kim
Hyun-Jung Byun
Sang-Hoon Kim
Han-Hyoung Lee
Suk Jun Lee
Sang Joon Kim
Chung-Gyu Park
Taehoon Chun
机构
[1] Korea University,Division of Biotechnology, College of Life Sciences and Biotechnology
[2] Seoul National University College of Medicine,Department of Surgery
[3] Seoul National University,Department of Microbiology and Immunology, College of Medicine
来源
Biotechnology Letters | 2010年 / 32卷
关键词
Co-receptor; Lymphocyte activation gene-3; Mixed lymphocyte reaction; Pig; T cell activation; Xenogeneic response;
D O I
暂无
中图分类号
学科分类号
摘要
Lymphocyte activation gene-3 (LAG-3; CD223) is a transmembrane protein that is structurally similar to CD4. Since LAG-3 has a much higher binding affinity to MHC class II than that of CD4, several approaches using soluble LAG-3 were used to modulate immune responses by activation or inhibition of MHC class II expressing antigen presenting cells. In this study, we constructed soluble pig LAG-3 containing a critical binding site (D1 and D2 region) to MHC class II molecules, combined with a constant region of an immunoglobulin (Ig) heavy chain. Flow cytometry analyses indicated that soluble pig LAG-3 binds to both pig and human MHC class II molecules. Moreover, soluble pig LAG-3 can inhibit human lymphocyte proliferation in the human–pig xenogeneic mixed lymphocyte reaction in a dose-dependent manner. These results indicate that soluble pig LAG-3 may be useful for controlling the xenogeneic T cell immune responses between the human and pig.
引用
收藏
页码:203 / 208
页数:5
相关论文
共 50 条
  • [31] Lymphocyte activation gene-3 (LAG-3) regulatory T cells: An evolving biomarker for treatment response in autoimmune diseases
    Gertel, Smadar
    Polachek, Ari
    Elkayam, Ori
    Furer, Victoria
    AUTOIMMUNITY REVIEWS, 2022, 21 (06)
  • [32] Soluble CD30 and lymphocyte activation gene-3 (CD223), as potential serological markers of T helper-type cytokine response induced by acellular pertussis vaccine
    Ausiello, CM
    Palazzo, R
    Spensieri, F
    Urbani, F
    Massari, M
    Triebel, F
    Benagiano, M
    D'Elios, MM
    Del Prete, G
    Cassone, A
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2006, 19 (01) : 97 - 104
  • [33] LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3/TCR activation pathway
    Iouzalen, N
    Andreae, S
    Hannier, S
    Triebel, F
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2001, 31 (10) : 2885 - 2891
  • [34] Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
    Hamid, O.
    Weise, A.
    Kim, T. M.
    Mckean, M. A.
    Lakhani, N. J.
    Kaczmar, J.
    Papadopoulos, K. P.
    Chen, S.
    Mani, J.
    Jankovic, V.
    Kroog, G.
    Sims, T.
    Lowy, I.
    Gullo, G.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S905 - S905
  • [35] Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
    Hamid, O.
    Weise, A.
    Kim, T. M.
    Mckean, M.
    Lakhani, N.
    Crown, J.
    Kaczmar, J.
    Papadopoulos, K.
    Chen, S.
    Mani, J.
    Jankovic, V.
    Kroog, G.
    Sims, T.
    Lowy, I.
    Gullo, G.
    ANNALS OF ONCOLOGY, 2022, 33 : S1598 - S1598
  • [36] LAG-3, A NOVEL LYMPHOCYTE-ACTIVATION GENE CLOSELY RELATED TO CD4
    TRIEBEL, F
    JITSUKAWA, S
    BAIXERAS, E
    ROMANROMAN, S
    GENEVEE, C
    VIEGASPEQUIGNOT, E
    HERCEND, T
    JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 171 (05): : 1393 - 1405
  • [37] Soluble human lymphocyte activation gene-3 modulates allospecific T cell responses
    Subramanyam, M
    Wands, G
    Nabioullin, R
    Tapper, MA
    INTERNATIONAL IMMUNOLOGY, 1998, 10 (05) : 679 - 689
  • [38] Prognostic significance of lymphocyte activation gene-3 (LAG3 gene) in uveal melanoma patients
    Singh, L.
    Singh, M. K.
    Kumar, N.
    Jha, J.
    Lomi, N.
    Sen, S.
    Kashyap, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1463 - S1464
  • [39] Effect of recombinant soluble lymphocyte activation gene 3 protein (Lag-3) on natural killer cell function.
    Luo, S
    Nabioullin, R
    Tepper, MA
    BLOOD, 1996, 88 (10) : 631 - 631
  • [40] Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy
    Yu, Xiaojie
    Huang, Xiao
    Chen, Xiuxiu
    Liu, Jianfei
    Wu, Chenglin
    Pu, Qian
    Wang, Yuxiao
    Kang, Xiaoqiang
    Zhou, Lijun
    MABS, 2019, 11 (06) : 1139 - 1148